[illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible]:

* [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

* [illegible]
* [illegible]

[illegible]

[illegible] [illegible] [illegible] [

[redacted]

[redacted]

[redacted] · GHB / GBL · [redacted] (4-MMC) · [redacted] · MDMA · [redacted] · [redacted]

⚠ [redacted] — [redacted] | [redacted]: **112** '[redacted] **findahelpline.com** '[redacted]

[redacted]

[redacted]

[redacted].

[redacted]-[redacted] [redacted] [redacted] [

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]—[illegible], [illegible], [illegible] [illegible] [illegible]—[illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]: [illegible] [illegible] [illegible] [illegible]

[illegible], [illegible] [illegible] '[illegible]

⚠ [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] **GHB + METH =** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] **GHB +** [illegible] **=** [illegible] [illegible] '[illegible]' [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] **GHB** [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible]	[illegible] [illegible] [illegible]	**Response**
GHB [illegible] [illegible] (**[illegible]** [illegible] [illegible] [illegible] [illegible])	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible]	[illegible] [illegible] [illegible] 112 '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [

		[illegible] "[illegible]" [illegible]
[illegible]	[illegible]—[illegible], [illegible]	[illegible], PEP ([illegible] 72 [illegible]), [illegible], [illegible] RAINN [illegible]: 1-800-656-4673. [illegible] '[illegible] PEP [illegible]

[illegible]

[illegible] — 72 [illegible]

[illegible] 42, PEP [illegible] '[illegible]' [illegible]— [illegible] HIV [illegible] 72 [illegible] HIV [illegible]— [illegible] PEP [illegible]

[illegible]	[illegible]	[illegible]
PEP ([illegible])[illegible]	28 [illegible] HIV [illegible] 72 [illegible]	72 [illegible]— [illegible], [illegible], [illegible] HIV [illegible]: "[illegible] HIV [illegible] PEP [illegible]"
PrEP ([illegible]-[illegible])[illegible]	[illegible] (Truvada/Descovy) [illegible] (Apretude) [illegible] HIV [illegible] 99% [illegible] '[illegible] '[illegible]-[illegible]' [illegible]	[illegible], [illegible] PrEP [illegible], [illegible] PrEP [illegible], [illegible]
[illegible] (STI) [illegible]	[illegible], [illegible], [illegible], [illegible], [illegible], [illegible] A [illegible] B [illegible]	[illegible] 3 [illegible], [illegible]-[illegible]

	[illegible]	[illegible]— STI ([illegible]) [illegible] HIV [illegible]
U=U ([illegible] = [illegible]-[illegible])	[illegible] (200 [illegible]/[illegible]), [illegible]—[illegible] PARTNER [illegible] PARTNER2 [illegible]	[illegible]: [illegible] '[illegible], [illegible]

[illegible] — [illegible] GHB [illegible]

Naloxone (Narcan) GHB [illegible], [illegible]—[illegible]— [illegible] Naloxone [illegible], [illegible]

[illegible] Never Use Alone [illegible]: 1-800-484-3731.

[illegible] 1 — [illegible] [illegible], [illegible] [illegible] [illegible]

[illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] - [illegible] [illegible], GHB/GBL, [illegible] [illegible] ([illegible] [illegible], MDMA, [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]) - [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] / [illegible]	[illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

- [illegible]: [illegible] [illegible] [illegible]

	[illegible] [illegible]	[illegible] [illegible]	[illegible]:
GHB / GBL	[illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] 3 [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] 2-72, [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible]	[illegible] [illegible], [illegible]-[illegible], [illegible], [illegible] [illegible]-[illegible] [illegible], [illegible] [illegible] [illegible], [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] GHB [illegible] [illegible]
[illegible] [illegible]	[illegible] [illegible] — [illegible] [illegible] '[illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] 1-14 [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible]	[illegible] [illegible] [illegible] [illegible] [illegible] (GHB), [illegible] [illegible], [illegible], [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] '[illegible]' [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
[illegible] / [illegible]	[illegible] - [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] 1-5 [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible], [illegible], [illegible], [illegible], [illegible], [illegible] [illegible], [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]— [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
MDMA ([illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible])	[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] 3-7 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]	[illegible] '[illegible]' [illegible] ([illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]), [illegible], [illegible] [illegible], [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible]: [illegible] [illegible] [illegible]

□□□ □□□□ findahelpline.com '□□ □□□ □□ □□□□□ □□□□ □□ □□□□ □□□

□□ □□□□□□□ □□□□□□ □□ □□ □□□ □□□□□□□□□□□□□□□ □□□□□□□ □□□□ □□□□□ □□□□ □□: COMT Val/Val (□□□□□□ - □□□□□□□□ □□ □□□ □□□□ □□□ □□□□ □□□□ □□□□□□□ □□ □□□ □□□ □□□□□□□ □□) □□□ MTHFR □□□□□□□□□□□□ (□□□□□□□ □□□ □□□□□ □□□ □□ □□□□□□□ □□□ □□□□□ □□ □□□ □□□□□□□□□□□□□□ □□ □□□□□□□□ □□□□ □□□□□□ □□□□□ □□)□ □□□□□□ □□□□□□ □□ □□□□ □□□□□□□ □□□□, □□□□□□□□ □□□□□□ □□□□ □□□□□□ □□□ □□□ □□□ □□ □□ □□□□ □□□□□□□-□□□□□□□ □□□□□□ □□:

□□□	□□□□□□□	□□□□□□ □□□□□□ □□□ □□□□ □□□ □□□ □□□□ □□□□□□□ □□□□	□□□□□□ □□ □□□□□□□
COMT	Val/Val (rs4680) — □□□□ □□ □□□□□□□□	□□ □□□□□□□ □□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□□□□ □□□ □□□□ COMT = □□□ □□□□ □□□□□□□□ = □□□□□ □□□□□□ □□□ □□□□ □□□□ □□□-□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□□□ □□□□□□ □□ □□□ □□□□ □□ □□□□□□ □□□□□□ □□ □□□□ □□□ □□□□ □□ □□ □□□□□□□ □□□□□□□□ □□□□□ □□□□□□ □□□□ □□□	□□□□□□ □□□□□□□□□ □□□ □□□ □□□ '□□ □□□□□□□ □□□□□ □□□□□□ □□ — □□□□□□□, □□□□□ □□□□□□, □□□□□□□ □□□□□□□, □□□ □□□□ □□□□□ □□ □□□□ □□ □□□□□□ □□□ □□□□ □□□□□ □□ □□□□□□□ □□□□ □□□□□□□□□ □□□□ □□□□□□□, □□ □□□ □□□□□□ □□□□□, □□□□□ □□□□□□ □□□□ □□□□, □□□□ □□□□□ □□□ □□□□□
MTHFR	C677T (rs1801133) □□□ A1298C (rs1801131).	□□ □□□□□□□ □□□ □□□ '□□ MTHFR □□□□□□□□□□□□ □□□ □□□□□ □□□□ □□, □□ □□ □□□□□□□□□□□□ □□ □□□□□□ □□□□ □□□ □□ □□□□ □□□□□□□ (HIV) □□ □□□□□ □□ □□□□ □□□ □□□□□□□□□ □□— □□ □□□□□ □□□□□ □□ □□□□□□ □□□ □□ □□□ □□□□□, □□ □□□□□□□□□□□□□□□ □□ □□□□□□□□ □□□□ □□ □□□□□ □□□□□□ □□, □□ □□ □□□□□ □□□ □□□□ □□ □□□□ □□□□ □□□□□ □□, □□□□□□ □□□□□□□ (chemsex) □□□□□□□□ □□ □□□□ □□□	5-MTHF □□□□□□□□□□□□ □□□□ □□□□ □□□□□□□ □□ □□□□□□ □□ □□□□□□ □□□ □□□□□□□□□□□□□□ □□□□□□□□ □□ □□□ □□□□□ □□□ □□□ □□□□ □□□ □□ MTHFR □□□□□□□ □□□□ □□□□□ □□ □□□□□□ □□□ □□ □□□□□ □□□□ □□□□□□ □□—□□ □□□□□ HIV □□□□ □□□□ □□□ □□□□□□□ □□□□□ □□ □□□□□□□□□□□ □□□□ □□□ □□□□□ □□□ □□□□ □□□
GABRA2	rs279858 /	GHB □□ □□□□ □□	GABRA2 □□□□ □□□ □□□□ □□□ □□

	rs279845 □□□ □□□□ □□□□ □□□□□□□□□□	□□□□□□□ □□□ □□□□ □□□ □□ □□□□ □□ □□□ □□□□□□□ □□□ □□□-□□□□ □□□□ GABRA2 □□□□□□□□ □□□□ □□□□ GABAergic □□□□□□ □□□ □□ □□□ □□□ □□□□□ □□ — GHB □□□□□□ □□□□□ □□□ □□□□ □□□□□□ □□□□ □□□□□ □□, □□□ □□ □□□□□□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□□□□□ □□□□□ □□□ □□□□□ □□□□ □□□	□□□□ □□ □□ GHB □□ □□□ □□□ □□ □□□□□□□□ □□□□ □□□□ □□□□□□, PAWS (□□□□□□□□ □□□□□□□ □□ □□□□□ □□□□) □□□□□ □□□□□ □□ □□□□ □□, □□□ □□□□□□ GABA □□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□ □□□□ □□□ □□ GHB □□□□□□□□ □□□□□ □□□□□ □□ □□□□ □□□ □□ □□□□□□□ □□□□ □□—□□ □□□□□□□ □□□□□□ □□□ □□ □□□□ □□□□□□ □□□
DRD2 / ANKK1	Taq1A A1 □□□□ (rs1800497) — □□□□□□ □□□□□□□□□□ □□□□□□□□	□□□□ □□□ DRD2 □□□□□□□ □□ □□□□□ = □□□□□□ □□□ □□□□□□□ □□□□□ = □□□□ □□ □□□□□ □□□□□ □□□ □□□□□□□ □□□□ □□ □□ □□□ □□□ □□□ □□□ □□□□□□□ (chemsex) □□ □□□-□□□ □□□□□□□ □□□ □□□□□□□ □□ □□□□□□ □□ □□□ □□□ □□□□ □□□□□□ □□□ □□ □□□ □□□□□ □□□□ □□ □□□ □□□□□ □□□□□ □□□□□□□□□□ □□□	DRD2 A1 □□□□ □□□□ □□□□□□ □□□ □□ □□□□ □□□□ □□□□ □□ □□□□ □□ □□ □□□□□□□ □□□□ □□□ □□□□□ □□□□□, □□□□ □□□ □□ □□ □□□□□□□ □□ □□□□ □□□□ □□□□□□ □□□□ □□ □□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□ □□□□□□ □□□□ □□□ □□□□□□ □□□ □□□□□□ □□□ □□□□□□ □□□□□ □□□-□□□□ □□□□ □□□□□□ □□□
DAT1 / SLC6A3	10-□□□□□ VNTR □□□□ (rs28363170)	□□□ □□□□□□□□ □□□□□□□□□□□ □□□□□□□□ = □□□□ □□□□□□□□ □□□□□□□ = □□□ □□□□□□□ □□□□□□□□ □□□□□□□ = □□□ □□ DAT □□□□□ □□□ □□□ □□□□□□□□□□ □□ ADHD □□□ □□ □□□□□□ □□□□□ □□□□ □□ — ADHD □□ □□□ □□ □□□-□□□□ □□□□ □□□ □□□□□□□□□□ □□□□□□□ □□□□ □□□	ADHD □□ □□□□□□□ □□□□□□□ □□□ '□□ □□□□□□ □□□ □□□□ □□□□□ □□ □□□□ □□□□□□ □□, □□□ □□□□ □□□□□ "□□□□□□□" □□ □□□□□ □□ □□□ □□□ □□ □□□□□□□ □□ □□ □□□ □□□□ □□ □□□□□□□ □□□ ADHD □□□ □□□ □□□ □□ □□□□□ □□□□ □□□□ □□ □□□□ □□□ □□□-□□□□□□□□□□ ADHD □□□□ □□□□□□□ □□□□ '□□ □□□□ □□□□□ □□ □□□ □□□ □□ □□□□□ □□□ □□ □□□ □□□□ □□□ □□□□ □□□□ □□□
SLC6A4 / 5-HTTLPR	□□□□/□□□□ □□□□ — □□□ □□□□□□□□□ □□□□□□□□□□□ □□□□□□□□□□□	□□□ □□□□□ □□□□□□□□□□□□, □□□□ □□□ □□□□□□□ □□□□□ □□□□□ □□ □□□ □□□□, □□□ □□□□□□□□ □□□ □□□□□□□ □□ SERT	□□□□□□□□□ □□ □□□ □□□□□, □□□□□□□□ □□□□□ □□ □□□-□□□, SLC6A4 □□ □□□□□/□□□□□ □□□□□□□□ □□ □□□ □□□□□□□□□ □□□□□ □□□ □□□□□ □□□ □□□□□ □□ □□□□□ □□□ □□□□ □□□□ □□, □□□□□

		□□□□□ (□□□□□□ □□□□□□□□□□ □□□□□ □□□□ □□□□□□□□□□ □□□□□□□□ □□□□□ □□) □□ □□□□ □□□□□□ □□□□□□□□ □□□□ '□□, "□□□□□□/□□□□□□" □□□□□ □□ □□□□□□□□ □□□□□□□□□□□ □□□□ □□□□□□□□□ □□ □□□□□□□□□□□□□□ □□□□□□□□□□ □□□□ □□ □□□□□□□□□ □□□□□ □□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□□ □□ □□□□□ □□□□	□□□□□, □□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□□□□□□□ □□□□□□ □□□□□□□□□ □□ □□□□ □□□□
CYP2B6	*6/*6 □□□□□ □□□□□□□□□□□□□□□□□ (rs3745274)	GHB □□ □□□□□-□□□□□: □□□□□ CYP2B6 □□□□□□□□□□□□□□□□□ □□□□□ GHB □□□□ □□□□□□□□□□□□□ □□ □□□□□□ □□□□□□□□□ □□□□□ □□ □□□□□ □□□□ □□ □□□□□□□□□ □□□□□ '□□□□□□□□□□□□□ □□□□□ □□□□□' (Dissociative Logjam Risk) □□□□□ □□□□□□□□□ □□□□□□□ □□ □□□□ □□□□□□□□□ □□ □□□□ □□□□□, □□□□□ CYP2B6 □□□□□□□□□□□□□□□□ □□□□□ GHB □□ □□ □□□□□□ □□□□ □□□□ □□□□ □□□□□□ '□□ □□ □□□□□ □□, □□□□□ □□ □□□□□□□□ □□□□□ □□□□□□□	GHB □□□□□□□□ □□□□ □□□□ □□□□ □□ □□□□□ □□□□□ □□ □□□□□□□ □□□□□□ □□ □□□□□□□ □□□□□□□□: CYP2B6 □□ □□□□□ □□□□□□□□□□□□□□□□□ □□□□ □□□□□□□□□ □□□□□ □□□□ □□□□□□□□□ □□ □□□□ □□□□□□ □□ □□□□ □□□□□ □□ □□□□□ □□ □□□□□ □□□□□□□ □□ □□□□□□□□□ □□□□ □□□□□□□□ □□□□□ □□□□□ □□□□□□□ □□□□
FAAH	C385A (rs324420) — □□□□ FAAH □□□□□□□□□□□	□□□□□□□□□□□□□□□ □□□□□□□□□□□□ □□□□□ □□ □□□□□ □□□□□□□ □□ □□ □□□□□□□□ □□□□□□□ □□□□□ □□ □□□□□□ □□ □□□□□□ □□ (□□ □□ □□, □□□□ □□□□□ □□□□□□□□□ □□□□ □□□□□□□ □□□□□□□ □□□□ □□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□)□ □□ □□□□□□□□□□□□ □□ □□□□□□□□ '□□ □□ □□□□ □□□□□□□ □□—□□ □□□□□□□ □□□□□□□ □□□□□ □□□□ □□□□□□ □□ □□□□□□ □□□	FAAH A/A □□□□□ □□□□□□ □□□□□ □□□□□□□ □□□□□□□□□□ □□ □□□□□ □□□□□ □□□□□□ □□ — □□□□ □□□□ □□□□□□ □□□□□ □□□□□□□ □□□□ □□□□ □□□□□□ □□ □□□□□□□ □□□□□□□ □□□□ □□□□□□ □□, □□ □□ □□□□□□□ □□□□□□ □□□□ "□□□□□□□□" □□□□□□ □□□□□□□ □□□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□□□ □□□□□□ □□ □□□□□□ □□□□ □□□□□□ □□□□□ □□□□ □□ □□□□□□□□□ □□ □□□□□□□ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□□□□□□□□□□□ □□□□ □□□□□□ □□□□□ □□□

□□□□ 3 — □□□□□□ □□□□□□□□□ — □□□□□□□ □□ □□□□□ □□ □□□□ □□□□ □□□□

□□ □□□□□□□□□□ — □□□□ □□□□□□ □□□, □□□ □□□□□□, □□□ □□□□□□ □□□□□□

□□□□□□ □□□□□□ □□□ □□□ □□□□□□□ □□ □□□□□ □□□ □□□□□-□□□□□□ □□□□ □□□□□ □□□ □□□□ □□□□ □□ □□□□□ □□□□ □□□□ □□□□□□ □□ □□□□ □□□□□□ □□□□□ □□□□ □□□□□□ □□, □□□□□□□ □□□□ □□ □□□□ □□□□, □□□□□□ □□□□□ □□□ □□□□□ □□□□□□ □□ □□□□□□ □□□ □□ □□□□ □□□ □□□□ □□ □□□ □□□□ □□□□□—□□ □□□□ □□□□ □□□□□ □□, □□□ □□□□□□ □□□□ □□□ □□□□ □□□

□□□□□□□□□□ □□ □□□□□□: □□□□□□ GHB □□□ □□□□□□□ □□□ (□□□□□□ □□□□), □□□ □□□□□□ □□ □□□□□□ □□□ □□□□□□□□ □□□□□□□ □□□□□□ □□□, □□□ □□□ □□□□ □□□□-□□□□ □□□ '□□ □□□□□□ □□□ □□□□□□ □□□□□□ □□□□□□ □□□□□□□□□□ □□□□□

□□□□ 1: GHB/GBL - □□□□□□ □□□□□.

□□□□ □□□□□ □□□□□□□ □□□□ □□□ □□ □□□ □□□ □□□ GHB/GBL □□ □□□ □□, □□□ □□ □□□□□□ □□□□□ □□□□□□ □□□□□□ □□□ GHB □□ □□□□□ □□□ □□□□ □□ □□ □□□□□□ □□ □□□□□□□ □□ □□□□ □□ □□□ □□□□ GHB □□□□ □□□□ □□□□□ □□□□ GHB □□□□□□□□□□ □□ □□□□□□□ □□□□ □□□□ □□□:

- □□□□□□□□ □□□ □□□□□ □□ □□□□□□ □□□□ □□□□□□—□□ □□□□-□ □□□□ □□□ □□ □□ □□□ □□□□□□□ □□□□□□□□□□□□□□ □□□□□ □□□
- □□□□ □□□□□□□□ □□□□□ □□□□ □□, □□□ □□□□□□ □□□□□□□ □□□□□□□ □□□-□□□□□ □□□□ □□□□□□□□□□□□□□□ □□□□□□□□□□
- GABRA2 □□□ □□□□ □□□□ □□ □□□□□□ □□ □□□□□ □□□□ □□ □□□□□ □□□□□ □□ □□□□ □□□□ □□□□□□□ □□□□□ □□—□□□ □□□□ □□□□□□ □□□□□□□□ □□ □□□□ □□□ □□□ □□□□-□□□□ □□□□□ □□□□ □□□□□ □□□
- □□□□□□□□ □□□□ □□□ 1 □□□ □□□□□: □□□□□□□□□□ □□□□□□□□□ (400–600mg, □□□□□ □□□□), P5P (25–50mg), 5-MTHF (400mcg), L-□□□□□ (200–400mg, □□□□ □□□ □□□□)□
- □□□□□□ (□□□□□ □□□ □□□□□) □□□□□ □□ □□□□□□□ □□ - □□ □□□□ □□□ □□□□ □□□□ □□ □□□ □□□□-□ □□□□□□ □□□ □□□□□ □□□ '□□ □□□□□ □□□□ □□□
- □□□□□□□□, □□□ □□ □□□□ □□□□ □□□ □□□ □□□□ □□□□□□ □□ □□□□ □□□□ □□□□ □□□□□□□□□ □□□ □□□□□ □□□ □□□

□□□□ 2: □□□□□□□ □□□□□□□□□□□□□ - □□□□□□□□ □□ □□□□ □□□□□□□

□□□ □□ □□□□ □□□□ □□□□ GHB □□ □□□□□□ □□□□□□□ □□□ □□□□□ □□□□□ □□□ □□□ □□□ □□□ □□□□ □□□-□□□□□□ □□□□ □□□ □□□□□ □□□□□□ □□□□□ □□□□ □□□□□— □□ □□ □□□□□ □□ □□□□□□ □□□□ □□□□□ □□□ □□□□ □□□ □□ □□□ □□□ □□□□ □□ □□□□ □□□□□□ □□ □□□ □□□□□ □□□□□□ □□□□□□ □□□□□□ □□□ □□□ □□ □□ □□□□□ □□□□

- □□□□□□ □□□ □□□ □□□: □□□□□□□□□□ 01 (□□□□□□), □□□□□, □□□□□□□□□□, □□□ □□□□ □□□□ □□□□ □□□ □□□ □□□□□□□ □□□ □□□□□ □□□□□

- [illegible] (500–1000mg, [illegible], [illegible] [illegible]): [illegible] [illegible] — [illegible] 3-5 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible]
- NAC (600mg, [illegible] [illegible] [illegible], [illegible] [illegible]): [illegible] [illegible]; [illegible] [illegible]
- [illegible] + [illegible].[illegible].[illegible] + [illegible].[illegible].[illegible]-[illegible] ([illegible] [illegible]): [illegible]2 [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]—BDNF [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- Semax ([illegible] [illegible] [illegible] [illegible] [illegible]): BDNF [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible]
- BPC-157: [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] 3: [illegible] [illegible] - [illegible] [illegible]-[illegible]

[illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] ([illegible] [illegible] [illegible]), [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

			[illegible]
[illegible] 0-72	[illegible]	[illegible]	[illegible]
[illegible] 3–7	[illegible] GABA [illegible]	[illegible] 01. [illegible] NAC [illegible]	[illegible] 5-HTP [illegible]
[illegible] 1-4	GHB [illegible] Selank [illegible] Epitalon [illegible] GABA [illegible]	[illegible] - [illegible] NAC [illegible]	[illegible] 5-HTP [illegible]
[illegible] 1–3	GHB [illegible] GABA [illegible] PAWS (Post-Acute Withdrawal Syndrome) [illegible] - [illegible] - [illegible] 4-7-8 [illegible] Selank [illegible]	D2 [illegible] - [illegible]	[illegible]
[illegible] 3–12	GHB [illegible]	[illegible]	[illegible]

	□□ □□□□ □□ □□□□ □□□□ □□□□□□ □□□ □□□□□ □□□□□ □□ □□□□ □□□ □□□ □□ □□□□□ □□□ □□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□ GABA □□ □□□□□□□ □□□ □□□□□ □□ □□□□□ □□□ PAWS (Post-Acute Withdrawal Syndrome) □□□□□ □□□□□□□ □□□□□□□□□ □□ □□□□□□ □□□	□□□□□□□□ '□□ □□ □□□□ □□ □□ □□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□ □ □□□□ □□□□ □□□□□□ □□□□□□ "□□□□□□□□□" □□□□ □□ □□□□□ □□□□ □□□□ □□□□ □□□□□ □□ □□□□□□□□□ □□□□□□□□ □□□□□ □□ □□□□ □□□□ □□ □□□□□ □□□□	□□□□□ □□□□ □ □□□□ □□□□ □□□□□ □□□□ □□□□□□, □□□□□□□ □□□□- □□□□□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□□□□□ □□□□□□ □□□□□□□ □□□□□ □□ □□□□□□ □□ □□□□□□ □□□□ □□□□□ □□□□□□□□ □□□□□ □□□□ □□□□□ □□□□

[illegible] — [illegible]-[illegible] — [illegible]

[illegible] GHB, [illegible], [illegible]/[illegible] [illegible], [illegible]-[illegible] [illegible] GABA-B [illegible] (GHB [illegible]), [illegible] D2 [illegible] ([illegible]), [illegible] ([illegible]/MDMA [illegible]) [illegible] - [illegible]

4.1 — [illegible] — [illegible]

[illegible]	[illegible]	[illegible]	[illegible] '[illegible]
5-MTHF (L-[illegible])	400–1000 mcg [illegible]	[illegible]	[illegible] '[illegible] MTHFR [illegible] (mucosal) [illegible] 5-MTHF [illegible] '[illegible] - [illegible] '[illegible] - [illegible], [illegible], [illegible]
[illegible] (B12)	1000–2000 mcg [illegible]	[illegible]	5-MTHF [illegible] ([illegible], [illegible], GABA [illegible]) [illegible]-[illegible] B12-[illegible] '[illegible], [illegible]-[illegible]
P5P ([illegible] B6)	25–50mg	[illegible]	GABA [illegible] (GHB [illegible]), [illegible] (meth [illegible]), [illegible]

			(mephedrone □□□□) □□□□ □□□□□ P5P-□□□□□□ □□□□□□□□□ □□□□ □□□□□ □□□□□ □□□□□ □□□□ □□□ □□□ □□□ □□□□□□□ □□□ □□ □□□□□ □□□□□ □□□□ □□□□ □□□□□ □□□
□□□□□□□□□□ □□□□□□□□□□	400-600 □□□□□□□□□ □□□□□□□□□	□□□□□ □□□ □□□□ □□□□	□□□ □□□□□ □□□□ □□□□□ □□□□□ □□ □□□□ □□□□ □□□□□ □□□□□ □□ □□□□□□□ □□ □□: GABA-B □□□□□ □□ □□□□□ (GHB □□□□□) □□□ NMDA □□□□□□□□□ / □□□□□ □□□□□ (□□□ □□□□□ □□□□ □□□□□)□ □□ □□□□□□□□□□□□ □□□□□ □□ □□ □□□□ □□□□ □□ - □□ □□ □□□□□□□□ □□□ □□□ □□ □□□ '□□ □□ □□□□□ □□□ □□□□□ □□□, □□□□ □□□□□ □□□ □□□ 1 □□□ □□□□□ □□□□

4.2 — □□□□□□□□□□ □□□□□□□□□□□□□□ □□□□□

□□□□□□□□	□□□□	□□□□	□□□□ □□□□□	□□□□
L-□□□□□□□□	500–2000mg	□□□□□, □□□□□□□ □□□ □□□□	□□□ / □□□□□□□□	□□□□ □□□ □□□□□ □□□ □□□, □□□□ □□□□□ □□□□□ □□□ □□□□ □□ □□□ □□, □□□□□ □□□□ □□□□□□□ □□ □□□□ - □□ □□□ □□ □□□□□□□ □□□□ □□□ □□□□ □□□□ □□□ □□□ □□□ □□□□ □□□ □□□□□ □□□ □□□ □□ □□ □□□□ □□□□□ □□ □□□□
NAC	600-1200 □□□□□□□□□, □□□ □□□□ 2 □□□□	□□□□ □□□ □□□□, □□□□ □□□□□	□□□□ □□□□	□□□□□□□ □□□□□□□□□□, □□ □□ □□□□□ □□ □□□□□ □□ □□□□□□□ □□□ □□□ 1 □□□ □□□□□ □□□□ □□□□ □□□□ □□□ □□□□ □□□□□□ □□□□ □□□□□□□ □□□□ □□□□ □□□□□ □□□ □□□□ □□ □□□□ □□□□□, □□ □□□□ (□□□□) □□ □□□□□ □□ □□□□ □□□
□□□□□□□ + □□□□□ + □□□□□□-□□□□□ (□□□□□ □□□□)	250mg UMP + 1g DHA + 250mg CDP-	□□□□ □□□□□	□□□ / □□□□□□□□	D1/D2 □□□□□□□ □□□□□□□□□□□□ - □□ □□□ □□□□□ □□□□ □□□

	choline			□□□□□□□□□ □□□□□ □□ □□□□□□□ □□□□□□ □□□ □□ □□□ □□□□ □□□□□□□□ □□, □□□ □□□□ □□□□□ □□□ □□□□□ □□□ □□□□ □□, □□ □□ □□□□□ □□ □□□ □□□□□ □□□□□□□ □□□ '□□ □□□□□□ □□□□□□□ □□□□□□ □□□□□ □□□
5-HTP	50–100mg	□□□□, □□□ □□□ 30 □□□□ □□□□□□□	□□□□□□□□□ / □□□□□□□ / □□□□□□□□□	□□□□□□□□□ □□□□□□□□ - □□ □□□□ □□□□ □□ □□□□□□□□□ □□ □□□ □□□ □□□ □□□□ □□ (□□□□□□□□□ + □□□□□□□ + □□□□□□ □□□□□)□ □□ □□□ □□□ □□□□ □□ □□□□□ □□ □□□□ □□□□□ □□□ □□□□□ □□ □□□□□ □□□□ □□□□ □□□□□ □□□□□ □□□
L-Theanine	200–400mg	□□□□ □□□ □□□, □□□ □□□ □□□□ 2-3 □□□□	GHB / □□□□□	□□□□ (GABA) □□□ □□□□□□□ (NMDA) □□□ □□□□□□□□ □□□ □□□□ □□□□□ □□□□□ □□□□ □□□□□ □□ □□□□ □□□□ □□□□□□□□ □□ □□□□□ (GHB) □□ □□□ □□□□ □□□ '□□ □□□ □□□□□□ □□□□ □□□□□□□□ □□ □□□□ □□□□□□ □□□ □□ □□□□□ □□□□ □□□□ □□□□ (GABA) □□ □□ □□□ □□□□ □□□-□□□□ □□□□ □□□□□ □□□
□□□□□□□	1-2 □□□□□ □□□□□□□□□	□□□□ □□□□	GHB / GABA	□□□□□ □□□□□□□ □□□□□□□; □□□□□-□□□□□□□; □□□ □□ □□□□□□□ - □□ □□□□ (GBL) □□□□ □□□□□□ □□ □□□□□□□ □□ □□□□ □□□□ □□□□□□□ □□□ □□□□□□□ □□□□ □□□ □□□□ □□□□□□ □□□□ □□□ □□□□ GHB □□ □□□□□ □□ □□□□□□□ □□□ □□□ □□□□, □□ □□ □□□□□□ □□□□□□ □□ □□□ □□□□□□
□□□□□□□□	4–12g	□□□□ □□□□	□□□□□□□□□ /	□□□□□□□□□ □□□□□□□

	(□□□□□□ □□□□ □□)□	□□□□□□ □□□□□□	□□□□□□□□□□	□□ □□□□□□□□□□□□□□; □□□□□□ □□□□□□□; □□□□□ □□ □□□□□□□ □□□□□□□□□ □□ □□□□□ □□ □□□ □□□□ '□□ □□□□□□□ □□□□□□ □□ □□□□□□□□□□ □□ □□ □□□□□□□ (□□□) □□□□□ □□ □□□ □□□□□□□□ □□□□□ □□□□□ "□□□□□□□□" □□ □□□□□□□□ □□□□□ □□□□□□ □□□
Omega-3 EPA + DHA	2-4 □□□□□□ □□□□□□□□□□	□□□□□ □□ □□□□, □□□□□□□	□□□□□ □□□□□	□□□□□□-□□□□□□□□□□□ □□□□□□□; BDNF □□□□□□□; □□□ (EPA-□□□□□□□); □□□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□□□□ (DHA)□ □□ □□□□□□□ □□□□□□□□ □□□□□□ □□□□ □□□□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□
□□□□□□□ □□□□ □□□□□□	500–1000mg	□□□□□□	□□□□ / □□□□□□	NGF □□□□ BDNF □□ □□□□□□□□ □□ □□□□ □□□□□□ □□□□□□□□□□□□□□□ □□ □□□□□□ '□□ □□□□□ □□□□ □□□□□ □□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□□□ □□□□□□ □□□□□□—□□□ □□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□□□□□ □□□□ □□□□□ □□□□□□□ □□□□ □□□□□ □□□□□□□ □□ □□□□ □□□□□□□ □□ □□□□□ □□□□□ □□ □□□□ □□□□ □□□□□□□ □□□□□□□□□□ □□□□□□□ □□□□ □□□□

4.3 — □□□□□□□ □□□□□

□□□□□□□□□	□□□□□□□□□ □□ □□□□-□□□□ □□□□□□□ □□□□□ □□□□□□□□□□	□□□□□ □□□□□□□	□□□□□
BPC-157	□□□□□□□□□□ □□□□ □□□□□□□□□□ □□ □□□□□□□; GABA-B □□□□□□□□□□; □□□□-□□ □□ □□□□□□□□ □□□□□□□; □□□□□-□□□□□□□□□□□□;	□□□□□ □□□□□□ - □□□□□□□□□□□	□□ □□□□ □□□□□ □□ □□□□□□□□ □□□□□□□ □□ □□ □□□□□□□□□ □□□□□□□ □□□□□□□□ □□□□□ □□ □□□□□□□ □□□□ □□□□□□ □□□□□□□□ □□□□□ □□— □□ □□□□□□□□□ (□□□), □□□□□□□□□□ (□□□□□□□□□□),

	[illegible] [illegible]		GABA-B (GHB), [illegible] [illegible] [illegible] [illegible] (or [illegible] [illegible] [illegible] [illegible]

[illegible] 5 — [illegible]

[illegible] — [illegible]

[illegible], [illegible] "[illegible]" [illegible] "[illegible]" [illegible] ([illegible]) [illegible]—[illegible], [illegible]—[illegible] '[illegible]

[illegible] '[illegible] 35S [illegible] ([illegible]) [illegible] V [illegible]

5.1 — [illegible]

[illegible] — [illegible]

[illegible]: [illegible], [illegible]

- HIV [illegible]: [illegible]/[illegible], [illegible] PEP ([illegible]-[illegible]) [illegible], [illegible] 72 [illegible] HIV [illegible]: [illegible] HIV [illegible], [illegible], [illegible] U=U (undetectable = untransmittable) [illegible]
- STI [illegible]: [illegible] ([illegible], [illegible], [illegible]), [illegible] ([illegible]), [illegible] ([illegible]), [illegible] ([illegible]), [illegible] C ([illegible] IV [illegible], [illegible] "[illegible]" [illegible]), [illegible] B ([illegible])[illegible]
- [illegible], [illegible]: [illegible]
- HPV [illegible], [illegible] ([illegible]-[illegible] 45 [illegible]): [illegible] HPV [illegible]
- [illegible], [illegible] (Jynneos) [illegible] "[illegible]" [illegible]
- [illegible] (CBC) [illegible], [illegible]

- [illegible]: [illegible] [illegible] [illegible] - [illegible] (GBL) [illegible] ([illegible] [illegible]) [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]
- [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] (ECG) [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] 3 [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] '[illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]—[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

5.2 — [illegible] [illegible] [illegible]

[illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] — '[illegible] [illegible] [illegible]'.

"[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: '[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] '[illegible] [illegible] [illegible] [

[illegible] [illegible] [illegible] [

□□□□ 6 — □□□□□□ □□□□ □□□□□□□ □□□ □□□□ □□□□□□□

□□ □□□□□□□□□ — □□□□□□□□□ **42** □□□□ — □□□□□□ □□□□□□□ □□□ □□□ □□□□□ □□ □□□ □□□□□□ □□ □□□□□□□ □□□□□□

□□ □□□□□□□ □□ □□□□□□□□□ 42, □□□□□□□ □□ □□□□□□ □□□ □□□□□□□ □□ □□□ □□□□ □□□□□□□ □□□□□□ □□□□ □□□ □□ □□□ □□□□□ □□□ □□□ '□□ □□□□□□ □□□□□□ □□ □□□□ □□□□ □□□

6.1 — □□□□ □□□□□ □□□□□□□ □□□□ □□□

- PrEP (□□□□-□□□□□□□□ □□□□□□□□□□□□): □□ □□□□□ PrEP □□□□ □□ □□□ □□ □□□ □□□□□ '□□□□□□□' □□□□ □□□□□ □□ □□□ □□, □□□ □□□□ □□ □□□□ □□□□□□□□ □□□□□□□ □□□ □□□□□□ PrEP □□□□□ □□□□ □□ □□□□□□□ □□□□ □□□□□ '□□□□-□□□□□□□□□ □□□□□□□' □□□□ □□□ □□□ Truvada □□□ Descovy (□□□□□□□ □□□□ □□□□□ □□□ □□□□□□ □□□□□□) □□□ Apretude (□□□□□□□□, □□ 2 □□□□□□□ □□□□) □□ HIV □□□ 99% □□□ □□□ □□□□□ □□□□□□ □□□□ □□ □□□□ □□□□□□ □□□ □□□□□□ □□□ '□□ □□□□□ □□□□□ □□ □□□□□□ □□□□□□ □□□□□□□ □□□□□, □□□□□□□□ □□□□ □□□□□□ □□□ HIV □□□□ □□□□□ □□□□□ □□□□□ □□□
- PEP (□□□□□□□□ □□□ □□□□ □□ □□□□□□): □□□□ □□□□□□□ □□□□□□ □□□□□ □□□□□□□ HIV □□ □□□□□□□ □□□□ □□, □□□ PEP 72 □□□□□□ □□ □□□□ □□□□□ □□□□ □□ 28 □□□□□ □□ □□□□ □□□ □□□□□ □□□□ □□□□□ □□□□ □□□□□□, □□□□ □□□□□□□□□□□□ □□□□□□ □□□□ □□ □□□□□□□□ □□□□□ □□□ □□□□□□□ □□□□ □□□□□□ □□□□ □□□□□□
- □□□□□ □□□□□□□ □□□□□□□: □□□□ □□□□□ □□□□□□□□ □□□ '□□ □□□□□ □□, □□□ □□□□ 3 □□□□□□□ □□□□□ □□□□ □□□□□□ □□ □□□□ □□□□□□□ □□□ 18-45 □□□□□ □□□□ □□ □□□ □□□□ □□□ □□□ □□□□□□ □□□□ □□ '□□□□□ □□□□□□' □□□ □□□□□□ □□□□ □□ '□□□□□ □□□□□□' □□□□□ □□□□□ □□□
- □□□□□□□□□□ □□ □□ □□□□□□□: □□□□ □□□□□ □□□□ □□□ □□ □□□□□ □□ □□□□ □□□□□□ □□ □□□ □□ (IV □□□□ □□□□□), □□□ □□ □□□□□□ '□□□□□□□' □□□□□ □□ □□□□□ □□, □□□ □□□□□□□□□□ □□ □□ □□□□ □□ 3 □□□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□□□□ □□ □□ □□□□ □□□□ □□ □□□□ □□□ □□□□□□□-□□□□□□ □□□□□□□□□□ □□□□□□ □□□□□□□□ □□□□□□□ □□□□ 8-12 □□□□□□□ □□□□ □□□□ □□□□□ □□□□□□□ □□□ □□□□ □□□□□□□ □□□ □□□□ □□□□□□□ □□□□ □□□□ □□□ □□ □□ □□□□ □□□□□□□ □□ □□□□ □□□ □□□□□□ □□□

6.2 - □□□□ □□□□□ □□□□□□□ □□□□□□□□ □□□

□□ □□□□□□□ □□ □□□□□□□: "□□□ □□□□□□□ □□□□□□□□ □□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□ □□, □□ □□□□ □□□□ □□□□□ □□□□□ □□□□ □□ □□□□□ □□ □□ □□ □□□ □□□□ □□□□ □□□□ □□ □□□ □□□□ □□□□□ □□□□ □□ □□□□□" U=U □□□ □□□□ □□□□□ □□ □□□□□□ □□□□ □□□ □□ □□□ □□□□□□□ □□□ □□ □□□□□□ PARTNER □□□ PARTNER2 □□□□□□□ □□□□□ □□□□ □□□□ □□□ □□, □□□ □□□□ □□□□□□□ □□□□□□□□□□ □□□□□□ □□□ □□ □□□□□ □□□ □□□□-□□ □□□□ □□□ □□□

- □□□□ □□□□□□□ □□□ □□ □□□□ □□□□□□□ □□ □□□ □□□□ □□□ □□: □□□ □□□□□ □□□ □□□□□□□ □□□□□ □□□ □□□□□□□ □□□□□□ □□□ □□□□□ □□□□ □□□□□□□□ □□ □□□□□□□

[illegible] [illegible] [illegible] [

[illegible] 7 — [illegible] [illegible] [illegible] — [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]-[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [

	[illegible] [illegible] [illegible]

□□□□□ □□□' □□□ □□□, '□□□□□□□ □□□□□□ □□□□' □□ □□□□□□□□□□ □□□□ □□□□□ □□□□□□□ □□□

2. □□□□□ □□□ □□□□□□□□ □□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□□ □□ '□□ □□, □□□ □□□□ □□□□ □□□□ □□□□ '□□ □□— □□□□□ □□□□ □□□□□□ □□□□ □□□□□ □□□□□□□□□ □□□ □□□□ □□ □□□□□ □□— □□□□ □□□ □□□ □□□ □□□□□ □□□ □□□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□□ □□□
3. 4-7-8 □□□ □□□ □□ □□□□ □□□—□□ □□□□□ □□□□□□ □□□□ □□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□ □□□□□□□□□□□□□ □□□□□ □□ □□□□□□ □□□□□ □□□ 4 □□□□, 6 □□□□ □□□ □□□ □□ □□□□ □□ □□□□□□□□□□□□□ □□□□ □□□ □□□□□□□□□ □□□□ □□ □□□□
4. NAC, L-Theanine, □□□ □□□□□□□□□□ □□□ □□□□□□ □□□□□□ □□□□□□ □□ □□□□ □□ □□□□□ □□□□□ □□, □□□□ □□□ □□□□□□□□□□ □□□□□ □□ □□□□□□ □□□ □□□□ □□□□ □□□□□□□ □□ □□□□ □□□ □□ □□□□ □□ □□□ □□□□□ □□□ '□□ □□□□ □□□ □□□□ □□□□□□□□ □□ □□ □□□□-□□□□□ □□□□ □□ □□□□ □□ □□□□□□ □□□
5. □□□□□ — □□□ □□□ '□□ □□□□□□ □□□□□□□□ □□□□□□ □□ □□□□ □□□□□□□ □□□□□ □□□□ □□□ □□ □□□□ □□□□□ □□□□□ □□□□□ □□ □□□□ □□ □□ □□□□□□ □□□□□□ □□□ □□□□ □□□□□□ □□□ □□□ '□□, □□□ □□□□□ □□□□□□ □□□□□□ □□□□□□□ □□□□□□ □□ □□□ □□□□□ □□□□□□□ □□□ □□□□□□, □□□ □□□□□□□□ □□□□ □□□□, □□□ □□□□□□ □□□□ □□ □□ □□□□□□□ □□□ □□□□□ □□, □□□ □□□ □□□□□□□-□□□□□□ □□□□□□□□□□
6. □□□-□□□□□□ □□□□ □□□□□□ □□□□□ □□□ □□□□□ □□□ □□□ □□□□ □□□□ □□□□□□ □□□□— □□ □□ □□□□□□ □□ □□□□□□ □□ □□□□□ □□□ □□□□□ □□□ □□□□ □□□□, □□□□ □□□□ □□□□ □□□□□□, □□□□□□□ □□□, □□□ □□□□□□□□□ □□□□□□□□□□ □□□□ □□ □□□□□ □□ □□□□ □□□ □□□ □□□□ □□□□□ □□□ □□□□, □□□□ □□□□-□□□□ □□ □□□□ □□ □□□ □□□
7. □□ □□□□ □□□□ □□□ □□? □□ □□□□□ □□□ □□□ □□ □□□□□□□ □□ □□□□ □□? □□□□□ □□ □□□□? □□□□□□□ □□ □□□□□□ □□□□ □□ □□□□□ □□□? □□□□ □□□□□□□ □□□□, □□ □□□□ □□□□□□ □□□ □□□□□□□ □□ □□□□ □□□ □□□□□ □□□□□—□□□□□, □□□□ □□□□ □□□ □□□— □□□□ □□□□□□ □□□ □□ □□□□ □□□□□ □□□□□□ □□□ □□□□ □□ □□□□□

[illegible] 8 — [illegible], [illegible], [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] — [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]; [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

[illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]: [illegible] [illegible] [illegible] [illegible], [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible], [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible]

> [illegible]

[illegible]

[illegible]

[illegible]

[illegible]

□□□□ 9 — □□□□□□ □□□□ □□□ □□□□□: □□□□□□ □□□□□□□□□ □□□.

□□□□□□ □□□□□□ □□□ □□□ □□□□ □□□□ □□ □□□ □□□ □□□□□ □□ □□ □□□□ □□ □□□ □□□□□□□□ □□□□□□□□□□□ □□□□□ □□□ □□□□ □□□□ □□ □□□□ □□□□ □□□□□□ □□□□□□□ □□□-□□□ □□□□□□ □□□□ □□□□□ □□ □□□ □□ □□□ □□□□□ □□□□□□ □□□□□□ □□□ □□□□□ □□□

□□□□	□□□□□□□□□□	□□□□ □□□□□	□□□□□□□ □□□ □□□□ □□□□
□□□□□ □□□□□□ □□□□□ □□ □□□ (0-7 □□□)	□□□□□□ □□□□ (□□□ 3); □□□□□□ □□□□□□□□; □□□□□□ □□□□ □□□□□	GHB □□ □□□□ □□□ □□□□ □□ □□□□ □□ □□□□; □□□□□□□/□□□□□□ □□ □□□□; □□□□ □□□ □□□□ □□□ PEP (□□□□-□□□□□□□ □□□□□□□□□□); PrEP (□□□□-□□□□□□□ □□□□□□□□□□) □□ □□□□□□□	□□□□□ 72 □□□□ GHB □□ □□□□ □□□ □□□□ □□□□□□ □□□□□ □□□□□□ □□□□ □□ □□□ □□□□, □□□□ □□□□□ □□□□□ □□□□□ □□□ □□ □□□□□ □□, □□□ □□ □□□ □□□□□□□□ □□□□□ □□□□□□ □□□ □□□□□ HIV/STI □□ □□□□□□□ □□□□□ □□□
□□□□□□□□□ □□□□ (□□□ 1-14)	□□□□□□□□□ 07, 09, 17, 18; □□□□□□□□ □□□□□□□□ □□□□ (□□□□ 4)	□□□□-□□□□ □□□□□□□□ □□□□; □□□□□; □□□□□□□□; □□□□; □□□□□□□□□ - □□□□ 1	NAC □□□ □□□□□□□□□ □□□ 1 □□□ - □□□□□ □□ □□□□□ □□□ □□□ □□□□ □□□□□□ □□□□□ □□□□□□□ □□□ 3-5 □□□ □□□□□ □□□□□ □□□ 5-HTP □□□ 1 (□□□□) □□□ □□□□□ □□□□□ □□□ □□□□□□ □□□□□ □□ □□□□□□□ □□ □□□□ □□□□□ □□□□□ □□□
□□□□□□ □□□ □□□□□□□□□ □□□□□□□□□ (□□□ 1-30)	□□□□□□□□□ 05, □□□□□□□□□ 08	□□□ □□□ □□□□□ □□□; □□□□□ □□□□□□□ □□ □□□□ □□□□ □□□□□□; □□□□□□□ □□□ □□□□□□; □□□□□ □□□□ □□ □□□□□ □□ □□□□□□□	□□□□ □□□ □□□□□ 24 □□□□□□ □□ □□□□ □□□□□□ □□□□□□ □□□ □□ □□□□ □□□□ □□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□ □□□ '□□ □□□□□□ □□□□□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□ - □□ □□, □□□□□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□□□ □□□ □□ □□□□□ □□□□ □□□□ □□□□□□ □□□ □□ □□ □□□□□ □□ □□□□□□ □□□□ □□□ □□□□□ □□□□□□ □□□ □□ □□□□□ □□ □□□ □□□□ □□□ □□□ □□□□□□□□ □□□□□ □□□
□□□□□□□□ □□□□□□ (□□□□□ 1-4)	□□□□ □□□: □□ □□□□□□□ □□□□□ □□□□□□□ □□□□□ □□□□ □□ □□□□□ □□□□ □□□ □□□□□ □□□□□□□ □□□□ □□	COMT, GABRA2, MTHFR, DRD2, SLC6A4, CYP2B6	GABRA2 □□□□ □□□ □□□□ □□□□, □□□□□□ □□□ □□ GHB □□ □□□□□□□ □□ □□ □□□ □□□□□□□□□ □□□ □□□ COMT Val/Val, □□□□□□□□□ □□□□□□□□□ □□□□ □□□□□□□ □□□□□ □□□ MTHFR □□ □□□□□ 5-MTHF □□□ □□□□□□ □□□□□□□ □□□ SLC6A4 □□□□□/□□□□□, □□□ □□□□□ □□□□□□□□□-□□□□□□□ □□□□□□□□ □□ □□□□ □□□□ □□ □□□□□□ □□□ □□□□□□□□□-□□□□ □□□□□□ □□ □□□

	□□□□□□□ □□□□□ □□□□□□□□□□ □□, □□□ □□□□□□ □□□□□ □□□□□□ □□□□ □□□□□□ □□□□□ □□ □□□□□ □□ □□□□ 15 (□□□□□□□□□), □□ □□□□□ □□ □□□□ 2.		□□□□□□ □□□□
□□□□ □□□□□ □□□□ □□□□□□□□ □□□□□□□□ (□□□□ □□□□□)□	□□□□□□□□□□□□ 42 (□□□.□□.□□. □□□□□□□□); □□ □□□□□ □□ □□□□ 5 □□□□ 6; □□□□□□□□ □□□□□ □□□□□□□□	PrEP □□□□ ART □□ □□□□□□□□ □□□□□□; □□ □□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□ □□□□□□□□; □□□□ □□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□□□ □□□□□□ □□□□□; "□□□□□□" □□□□□ □□□□□□□□□ □□□□ □□□□□□□ □□ □□□□□□□□	□□□□□□□□□ □□□□□ □□□□□□□□□ □□□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□ □□—□□ □□□□□ □□□□□□□ □□□□□ □□□□□ □□□□□, □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□□□□□□□ □□□□ □□□□□□□ STI □□□□□□□□, □□□□□□□ PrEP □□□□ ART □□ □□□□□, □□□□ □□□□□ □□□□ □□□□ □□□□□ □□□□□□□□□ □□□□□□□ □□□□ □□□□ □□□□□□□ □□ □□□□□ □□ □□□□□ □□□□□□□□□□□□ □□, □□□□□□□□□ □□□□□□□ □□□□□ □□□□□ □□□□ □□□□□ □□□□□ □□□□□□
□□□□□□□□□□ □□□□□□□□□□□ (□□□□□□ 2-12)	□□□□□□□□□□□□ 04, □□□□□□□□□□□□ 08, □□□□□□□□□□□□ 16; □□.□□□.□. □□□□ □□□□□ □□□□□□	□□□□ □□□□□□□□□□□□□+ □□□□□□□□□; □□□□□□□ □□□□□ □□□□□ □□□□□□□□ □□□□□ □□□□□□; □□□□□ □□□□□□□ □□□□□□	□□□□□□ □□□□□□□□ □□□□□□□ □□□□□ □□□□□□ □□□□□□□ □□□□□ □□□□□□ □□, □□□□□□ □□□□□□ □□□□□□ — □□□□□ □□ □□□□□□□ □□ □□□□□ □□□□□□□□ □□□□ □□□□ □□□□□□ □□□□□□□□ □□□□ □□□□□ □□ □□□□□ □□□□ □□□□□□□ □□□□□ □□□□□, □□□□□ □□□□ □□□□□□ □□□□□□ □□□□ □□□□□ □□□□□ □□□□□□□□ □□□□□ □□ □□□□□□□ □□□□□ □□□□ □□□□□□ □□ □□□□□□□□□□ □□□□□ □□ □□□□ □□□□□□□□□□ □□□□□□□-□□□□□□ □□□□□□□□□□ □□, □□□□ □□ □□□□□ □□□□□ □□ □□□□□□ □□□□ □□□□□□□□ □□□□ □□□□□ □□□□□ □□□□
□□□□□□ □□□□□ □□□□ □□□□□ □□□□ (□□□□□□ 2-12)	□□□□□□□□□□□□ 20, 21, 35S □□□□□□□□; □□□□□□□□□□□□□□□ + □□ □□□□□□ □□□□ □□□□□ □□□□□□□□	□□□□□□ □□□□□ □□ □□□□□□□□; □□□□□ □□□□ □□□□□□□□□□ □□□□□; □□□□□□□□ □□□□□□ □□□□□ □□ □□□□□□□; "□□□□□□□□□□" □□□□ □□□□□ □□□□□	□□□□□□□ VII □□□□□ □□□□□ □□□□□□□□ □□ □□□□□□□□□□ □□□□□□□□□□ 35S □□□□□□□ □□ □□□□ □□ □□□□□□□ □□□□□□□□ □□□□□□□ □□□□□ □□□□ □□□□ LGBTQ+ □□ □□□□□□ □□□□ □□□□□ □□□□ □□□□□□□ □□□□□ (chemsex) □□ □□□□□□ □□□□□ □□□□□□□□□ □□ □□□□□ □□□□□ □□ □□□□ □□□□□□ □□□□□□□□ □□□□□□ □□□□□ □□□□
□□□□□ □□□□□ □□ □□□□□□ (6 □□□□□□□□□ □□□□ □□□□)	□□□□□□□□□□□□ 24, 25, C-28, C-31; □□□□□□□□□□□□ 35S.d	□□□□□□□ □□ □□□□□□□ □□ □□□□□□□□□□□; □□□□□□; □□□□□ □□□□ '□□ □□□□□□, □□□□□□ □□□□ □□□□□□□ □□□□□ □□□□□□□	□□□□□□ □□□□□□□ □□ □□□□□□□□ □□□□ □□□□□ □□□□□ □□□□ □□□□□□ □□ — □□□ □□□□□ □□□□□□□□ □□□□, □□□□□□□□ □□□□□□□□□ □□□□□□□□ □□ □□□□, □□ □□□□□□□ □□□□□ □□□□□□ □□□□ □□ □□□□□□□ □□ □□□□□ □□□□□□ □□□□ □□□□□□□□ □□, □□□.□□.□□. □□ □□□□□ □□□□□□□ □□□□□□ □□ □□□□□□□□ □□□□□, □□□□ □□□□□□ □□□□□ □□□□□□□ □□ □□□□□ □□□□ '□□ — □□ □□□□□□□ □□□□□□□□ □□□□□ □□□□□□□ □□□□□□ □□ □□ □□ □□□□ □□ □□□□□□ □□□□□

			'□□ □□□□ □□□□ □□ □□□□□□□□ □□□□□□ □□□□ '□□ □□ □□□□□□□ □□ □□□□□□ □□□□ □□□□

[illegible]

[illegible]

[illegible] 1980 [illegible] 1990 [illegible]+ [illegible]

[illegible]

[illegible]

[illegible] GABA [illegible]

[illegible]

— — —

Crystal Meth Anonymous (CMA): crystalmeth.org | SAMHSA: 1-800-662-4357
Never Use Alone: 1-800-484-3731 | RAINN: 1-800-656-4673 | LGBTQ+ Crisis: The Trevor Project: 1-866-488-7386

Crisis: call or text 988 | Emergency: 911 | SAMHSA: 1-800-662-4357

[illegible]

⚠ [illegible] — [illegible]

[illegible]